Humanized pertussis antibodies and used thereof
The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
1. A method of treating a patient infected with Bordetella pertussis , comprising administering to the patient an effective amount of a humanized 11 E6 antibody comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein the immunoglobulin heavy chain variable region comprises an amino acid sequence SEQ ID NO: 18, and the immunoglobulin light chain variable region comprises an amino acid sequence SEQ ID NO: 23.
2. The method of claim 1 , wherein the humanized 11E6 antibody binds the pertussis toxin protein with a KD of 12 nM or lower.
3. The method of claim 1 , further comprising administering an effective amount of a humanized 1 B7 antibody, wherein the humanized 1B7 antibody comprises an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein the immunoglobulin heavy chain variable region comprises an amino acid sequence SEQ ID NO: 3, and the immunoglobulin light chain variable region comprises an amino acid sequence SEQ ID NO: 11.
4. The method of claim 3 , wherein the humanized 1B7 antibody binds to the pertussis toxin protein with a KD of 3 nM or lower.